Here's What Key Metrics Tell Us About Addus HomeCare (ADUS) Q4 Earnings

For the quarter ended December 2024, Addus HomeCare (ADUS) reported revenue of $297.14 million, up 7.5% over the same period last year. EPS came in at $1.38, compared to $1.32 in the year-ago quarter.The reported revenue represents a surprise of +1.71% over the Zacks Consensus Estimate of $292.16 million. With the consensus EPS estimate being $1.38, the company has not delivered EPS surprise.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.Here is how Addus HomeCare performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Personal care: $220.33 million compared to the $203.82 million average estimate based on two analysts. The reported number represents a change of +7.7% year over year. Revenue- Home Health: $17.83 million compared to the $17.29 million average estimate based on two analysts. The reported number represents a change of +4.1% year over year. Revenue- Hospice: $58.99 million versus $58.01 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +7.8% change. View all Key Company Metrics for Addus HomeCare here>>>Shares of Addus HomeCare have returned -16.4% over the past month versus the Zacks S&P 500 composite's -0.5% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.Just Released: Zacks Top 10 Stocks for 2025Hurry – you can still get in early on our 10 top tickers for 2025. Handpicked by Zacks Director of Research Sheraz Mian, this portfolio has been stunningly and consistently successful. From inception in 2012 through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Sheraz has combed through 4,400 companies covered by the Zacks Rank and handpicked the best 10 to buy and hold in 2025. You can still be among the first to see these just-released stocks with enormous potential. See New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Addus HomeCare Corporation (ADUS): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks